Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 12 Aug 2025 |
| Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) | 7 Aug 2025 |
| Genmab Announces Financial Results for the First Half of 2025 | 7 Aug 2025 |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025 | 16 Jul 2025 |
| Genmab Announces Changes to its Executive Committee | 1 Jul 2025 |
| Completion of Share Buy-back Program | 30 Jun 2025 |